Review



rabbit polyclonal anti ampk alpha 1  (Proteintech)


Bioz Verified Symbol Proteintech is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 96
      Buy from Supplier

    Structured Review

    Proteintech rabbit polyclonal anti ampk alpha 1
    Rabbit Polyclonal Anti Ampk Alpha 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 242 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha+1+Antibody/pmc12432379-19-0-6
    Average 96 stars, based on 242 article reviews
    rabbit polyclonal anti ampk alpha 1 - by Bioz Stars, 2026-10
    96/100 stars

    Images

    Related Articles

    other:

    Article Title: A CD147-targeted small-molecule inhibitor potentiates gemcitabine efficacy by triggering ferroptosis in pancreatic ductal adenocarcinoma
    Article Snippet: Rabbit Polyclonal anti-AMPK Alpha 1 , Proteintech , Cat# 10929-2-AP; RRID: AB_2169568.



    Similar Products

    rabbit anti ampk  (Bioss)
    94
    Bioss rabbit anti ampk
    Rabbit Anti Ampk, supplied by Bioss, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha-1+Polyclonal+Antibody/pm40065050-75-32-34
    Average 94 stars, based on 1 article reviews
    rabbit anti ampk - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    ampk alpha  (OriGene)
    93
    OriGene ampk alpha
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Ampk Alpha, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha+1+(PRKAA1)+Rabbit+Polyclonal+Antibody/pmc12719668-254-69-88
    Average 93 stars, based on 1 article reviews
    ampk alpha - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    phospho ampk alpha 1 2  (OriGene)
    93
    OriGene phospho ampk alpha 1 2
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Phospho Ampk Alpha 1 2, supplied by OriGene, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha+2+(PRKAA2)+Rabbit+Polyclonal+Antibody/pm41203135-224-55-80
    Average 93 stars, based on 1 article reviews
    phospho ampk alpha 1 2 - by Bioz Stars, 2026-10
    93/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti ampk alpha 1  (Proteintech)
    96
    Proteintech rabbit polyclonal anti ampk alpha 1
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Rabbit Polyclonal Anti Ampk Alpha 1, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha+1+Antibody/pmc12432379-19-0-6
    Average 96 stars, based on 1 article reviews
    rabbit polyclonal anti ampk alpha 1 - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti ampk alpha  (Proteintech)
    96
    Proteintech rabbit polyclonal anti ampk alpha
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Rabbit Polyclonal Anti Ampk Alpha, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/ENO1+Antibody/pmc12443895-7-0-6
    Average 96 stars, based on 1 article reviews
    rabbit polyclonal anti ampk alpha - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    ampk alpha 1/2, phospho‐ampk alpha 2, sirt1, pgc1 alpha, p53, gpx4, gapdh rabbit polyclonal antibodies, and goat anti‐rabbit igg hrp (zen‐bio)  (ZenBio)
    90
    ZenBio ampk alpha 1/2, phospho‐ampk alpha 2, sirt1, pgc1 alpha, p53, gpx4, gapdh rabbit polyclonal antibodies, and goat anti‐rabbit igg hrp (zen‐bio)
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Ampk Alpha 1/2, Phospho‐Ampk Alpha 2, Sirt1, Pgc1 Alpha, P53, Gpx4, Gapdh Rabbit Polyclonal Antibodies, And Goat Anti‐Rabbit Igg Hrp (Zen‐Bio), supplied by ZenBio, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/pgc+1%CE%B1+antibody/pm39865943-39-119-129
    Average 90 stars, based on 1 article reviews
    ampk alpha 1/2, phospho‐ampk alpha 2, sirt1, pgc1 alpha, p53, gpx4, gapdh rabbit polyclonal antibodies, and goat anti‐rabbit igg hrp (zen‐bio) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti ampkα  (Proteintech)
    95
    Proteintech rabbit polyclonal anti ampkα
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Rabbit Polyclonal Anti Ampkα, supplied by Proteintech, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha+Antibody/pmc11481753-74-79-84
    Average 95 stars, based on 1 article reviews
    rabbit polyclonal anti ampkα - by Bioz Stars, 2026-10
    95/100 stars
    		  Buy from Supplier
    rabbit polyclonal anti ampk  (Proteintech)
    96
    Proteintech rabbit polyclonal anti ampk
    <t>AMPK/mTOR</t> signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.
    Rabbit Polyclonal Anti Ampk, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/rabbit+polyclonal+anti+ampk+alpha+1/AMPK+alpha+1+Antibody/ppr0786046-195-20-23
    Average 96 stars, based on 1 article reviews
    rabbit polyclonal anti ampk - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier

    Image Search Results


    AMPK/mTOR signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.

    Journal: The Journal of Biological Chemistry

    Article Title: Metformin attenuates O-GlcNAc modification to improve renal function via AMPK/mTOR signaling in diabetic nephropathy

    doi: 10.1016/j.jbc.2025.110909

    Figure Lengend Snippet: AMPK/mTOR signaling pathway influences mesangial cell damage via O-GlcNAcylation under high-glucose treatment. A , representative Western blot images of four groups of O-GlcNAc, OGT, and OGA and AMPK/mTOR pathway proteins according to whether or not AMPK agonist and inhibitor were added, n = 3. B , representative quantification of O-GlcNAc, OGT, and OGA in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. C , mRNA expression of OGT and OGA assessed by RT-PCR, n = 3. D–F , representative quantification of p-AMPK, p-mTOR, and p-S6K in MCs of four groups according to whether or not an AMPK agonist and inhibitor was added, n = 3. G , the effect of AMPK agonist and inhibitor treatment on MCs volume under high glucose conditions, n = 3. H , the effect of AMPK agonist and inhibitor treatment on MCs viability under high-glucose conditions, n = 3. Data are presented as mean ± SD. Significance analysis was performed with one-way ANOVA (multiple comparisons). ∗ p < 0.05; ∗∗ p < 0.01; ∗∗∗ p < 0.001; and ∗∗∗∗ p < 0.0001. AMPK, AMP-activated protein kinase; CC, compound C; MC, mesangial cell; Met, Metformin; mTOR, mammalian target of rapamycin; OGA, O-GlcNAcase; OGT, O-GlcNAc transferase.

    Article Snippet: The following primary antibodies were used to detect the respective proteins after incubation overnight at 4 °C in 5% BSA: O-GlcNAc (#65292-1-lg, proteintech, 1:1000), OGT (# R25212 , Zen Bio, 1:1000), OGA (# R24971 , Zen Bio, 1:1000), Phospho-AKT (Ser473) (#310021, Zen Bio, 1:1000), AKT (# R23412 , Zen Bio, 1:1000), Phospho-mTOR (Ser2448) (#381557, Zen Bio, 1:1000), mTOR (#380411, Zen Bio, 1:1000), Phospho-AMPK alpha 1/2 (Thr183/Tyr172) (#340763, ZenBio, 1:1000), AMPK alpha (#23314, ZenBio, 1:1000), Phospho-P70 S6K (Thr389) (#AF5899, Beyotime, 1:1000), P70 S6K (#AF0258, Beyotime, 1:1000), and GAPDH (#TA802519, Origene, 1:1000).

    Techniques: Western Blot, Expressing, Reverse Transcription Polymerase Chain Reaction